Eukarys

Eukarÿs featured by NASDAQ in Times Square

Pixmaker — Wed, 26 Nov 2025 10:00:32 +0000

Nov. 26th, 10am local time in NYC, NASDAQ has featured Eukarÿs on its giant screen in Times Square, for having both:

1 – won the 2025 Grand Prize of Biotools Innovator, the only startup accelerator dedicated to Life Sciences Tools, after an extremely selective process, which had started early 2025 with 440 candidates from 43 countries,

2 – been selected by BARDA as member of the Vanguard acceleration program, focused on enabling technologies identified as critical for responsiveness in case of health crisis like pandemics or bioterrorist attacks.

Eukarÿs celebrated by the life sciences tools industry

Pixmaker — Sat, 15 Nov 2025 09:54:37 +0000

After an extremely selective process throughout the year 2025 Eukarÿs reaches a historic “double hit” in acceleration programs in the US

Eukarÿs is the Winner of the 2025 BioTools Innovator Grand Prize, receiving a $250,000 award. Eukarÿs was in competition with 440 companies from 43 countries. The final took place at the Capstone event in San Diego, where Eukarÿs was the only non-US company. The selection has been made by vote by 80+ industry-leaders of the Life-Sciences Tools industry.

And

2. Eukarÿs has been selected by the U.S. government agency BARDA as one of the ten startups admitted into VANGUARD, its accelerator dedicated to enabling technologies for national health preparedness.

These distinctions, both awarded in the United States, the world’s largest and most competitive biotech and bioproduction ecosystem, represent a remarkable recognition of Eukarÿs deeptech innovation on the global stage.

Press release

Eukarÿs appoints Nicole Faust and Bryan Poltilove as strategic advisors

Pixmaker — Sat, 01 Nov 2025 09:36:36 +0000

After having mentored Eukarÿs during the Biotools Innovator acceleration program, Nicole Faust and Bryan Poltilove join the company as strategic advisors.

As former CSO and CEO of CEVEC (acquired in 2024 by Cytiva, Danaher group), a world first technology cell line company, Nicole brings both her technical capabilities in cell line engineering and her successful experience in building a leader of the biomanufacturing technology.

As former VP/GM with Thermo Fisher and Operating Partner with BroadOak Capital, Bryan brings a rare combination of experience in business leadership, strategy, and investing in the field of biomanufacturing technology.

Eukarÿs strengthens its Board of Directors by appointing Eric Drape, world recognized expert of the biomanufacturing industry

Pixmaker — Sun, 01 Jun 2025 08:32:13 +0000

One year after the appointment of Gabriel Festocand Anne Lauvergeon as board members, Eukarÿs is pleased to announce a new step in the strengthening of its Board of Directors with the appointment of Eric Drapé.

As former EVP Operations of TEVA, Eric brings a deep knowledge of the biomanufacturing industry. Being board member of Lonza and of LFB, Eric also brings his rare experience in corporate governance in the biopharma and biomanufacturing field.

Genethon and Eukarÿs announce strategic partnership to develop breakthrough technology for lowering the biomanufacturing cost of biomanufacturing gene therapies

Pixmaker — Thu, 23 Jan 2025 08:00:00 +0000

Eukarÿs and Genethon have announced a strategic partnership to reduce the cost of gene therapy drugs production. By combining Eukarÿs’ innovative disruptive C3P3 technology, which enhances unleashes mRNA synthesis in mammalian cells, with Genethon’s expertise in AAV vector production, the partnership aims to significantly increase production yields, leading to more affordable and accessible gene therapies. Eukarÿs’ C3P3 enzyme can multiply the production yields of all other biomedicines by a factor of 5 to 7. Without requiring any adaptation or investment in new equipment, nor any changes toin existing industrial processes, thus changing the game improving the efficiency of biomanufacturing in biomedicines manufacturing. This collaboration will help accelerate the development of cost-effective gene therapies for patients in need, and contribute to make them accessible to a wider part of the global population.

Access the full Press Release FR/ EN:

French English

Philippe H. Jais, Speaker at the World Vaccine Congress in Boston

Pixmaker — Tue, 10 Dec 2024 13:09:31 +0000

We are pleased to share that Philippe H. Jais was a featured speaker at the World Vaccine Congress in Boston on November 12, 2024. As a recognized expert in biotechnology and medical innovation, Philippe presented on the topic: « In Vivo Synthesis of Messenger RNA by Artificial Expression System: Application to Vaccinology and Molecular. » During his talk, Philippe highlighted Eukarÿs’ pioneering advances in in-cellulo mRNA synthesis and its applications in vaccinology, which are already being utilized by a top-5 pharma company and over 25 major research organizations. The presentation provided valuable insights into the future of vaccine development and demonstrated the potential impact of these innovations on global health.

Partner publication highlights advances of C3P3 technology, for vaccine research

Pixmaker — Tue, 10 Dec 2024 13:08:18 +0000

A new study led by Washington University and published in Nature – Vaccines, highlights the use of C3P3 technology in vaccine research targeting rotaviruses. These viruses, which cause severe gastroenteritis, remain a major cause of infant mortality in developing countries.

The publication shows how C3P3 was used to produce the studied rotaviruses and highlights the greater efficiency gains brought by a more advanced C3P3 prototype (initial version of C3P3-G3) than the one used in previous studies by Stanford researchers (C3P3-G1).

For more information on the use of C3P3 in rotavirus vaccine research, see these previous publications:

https://pubmed.ncbi.nlm.nih.gov/32759316/

https://pubmed.ncbi.nlm.nih.gov/36821582/

Note: The commercial model of C3P3 further outperforms the prototypes.

Eukarys wins Sanofi’s Golden Ticket 2024: a wonderful recognition for Eukarÿs, and for the whole biomanufacturing industry

Pixmaker — Tue, 10 Dec 2024 13:01:26 +0000

Eukarys is pleased to announce that it has been awarded Sanofi’s Golden Ticket 2024, which provides one year of free laboratory space at BioLabs France Hôtel-Dieu. We are proud to be the first biomanufacturing technology start-up to receive this prestigious award: all previous winners were in the therapeutic or AI sectors. This recognition underscores the growing importance of biomanufacturing as a key area of innovation within the life sciences industry and confirms the transformative potential of our technology, and the achievability of Eukarÿs’ goal, to accelerate the development of more efficient and cost-effective biomanufacturing solutions, ultimately improving access to critical therapies for patients worldwide.

Eukarys receives DeepTech Development support from Bpifrance

Pixmaker — Sun, 01 Dec 2024 08:36:42 +0000

Eukarys is proud to announce a new milestone in its innovation journey with the support of Bpifrance as part of the DeepTech Development program and the France 2030 initiative. This recognition underlines our commitment to revolutionize biomanufacturing with our C3P3® technology, which enables higher yields and lower costs. Building on our history of innovation, Eukarys was previously honoured by Bpifrance as a winner of the prestigious i-Lab competition in 2009 and 2012. These achievements underline our long-standing commitment to developing cutting-edge technologies with high impact potential.

Eukarÿs strengthens Board of Directors with new appointments

Pixmaker — Tue, 16 Apr 2024 13:30:00 +0000

Eukarÿs is pleased to announce the strengthening of its Board of Directors alongside the appointment of Guillaume Prunier as CEO. Gabriel Festoc, PhD, former President of Polyplus (acquired by Sartorius in 2023 for €2.4 billion), is a leading expert in bioproduction technologies, particularly in cell & gene therapy. Anne Lauvergeon, representing ALP, brings her industrial and financial expertise. Formerly Managing Partner at Lazard and CEO of Areva, she is a strong advocate of innovation. These strategic appointments will help Eukarÿs leverage its cutting-edge C3P3® technology to revolutionize the biomanufacturing industry.